Long-term benefit of mycophenolate mofetil in renal transplantation.

The results of clinical trials of mycophenolate mofetil (MMF) and the analysis of numerous data from renal transplant registries have shown that MMF reduces the incidence of early and late rejection (even in the black population), is protective against long-term deterioration of renal function, and reduces late renal allograft loss independently of acute rejection without increasing the risk for malignancies.